Loading clinical trials...
Loading clinical trials...
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT02616302 · Gastroesophageal Reflux Disease (GERD)
NCT04506593 · Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), and more
NCT07174882 · Non-Erosive Gastro-Esophageal Reflux Disease, Gastroesophageal Reflux Disease (GERD)
NCT07344935 · Gastroesophageal Reflux Disease (GERD)
NCT07179250 · Incentive Spirometer, Diaphragmatic Breathing, and more
Research Site
Phoenix, Arizona
Research Site
Little Rock, Arkansas
Research Site
Wilmington, Delaware
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions